The Ebola virus break out in Western Africa controlled a lot of the stories in 2014. The highly catching virus spreads quickly and kills more than half of those people who get infected, resulting in heavy panics across multiple continents. While the majority of the dead are in Africa, health employees did bring the pathogen home to other states and continents.
For all of the problems and focus upon doomsday eventualities on what the virus could do, there are basically dome economic benefits of Ebola virus break outs. The economic benefits largely breakdown between non profit or government groups and for-profit biotechnology firms.
Executive or aid associations like the Red Cross or the CDC have a tendency to see increases in funding in events such as these. The industrial advantages to them are direct and help out those on the ground suffering or helping and containing an outbreak.
This containment keeps economic interruption when funding is acceptable to turn the tide of an onset.
The longer term business benefits of Ebola virus onsets are biotech corporations working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for larger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medications prove to be of value.
While the 2014 Ebola breakout is first to have captured global attention as much as it probably did, it was barely the first breakout. Others have happened, and more will happen in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in future times.
For all of the problems and focus upon doomsday eventualities on what the virus could do, there are basically dome economic benefits of Ebola virus break outs. The economic benefits largely breakdown between non profit or government groups and for-profit biotechnology firms.
Executive or aid associations like the Red Cross or the CDC have a tendency to see increases in funding in events such as these. The industrial advantages to them are direct and help out those on the ground suffering or helping and containing an outbreak.
This containment keeps economic interruption when funding is acceptable to turn the tide of an onset.
The longer term business benefits of Ebola virus onsets are biotech corporations working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for larger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medications prove to be of value.
While the 2014 Ebola breakout is first to have captured global attention as much as it probably did, it was barely the first breakout. Others have happened, and more will happen in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in future times.
About the Author:
my name is alfred obi i have been a biological scientist for years training people on ebola virus disease update and ebola virus disease that has affected most countries in africa be happy to come to my site for your free protective gear on ebola thanks.
No comments:
Post a Comment